Improving quality of the informed consent process: Developing an easy-to-read,multimodal, patient-centered format in a real-world setting

Objective

To develop a patient-centered informed consent and assessment tool written at a 6th grade-level that is multimodal, affordable, transportable, and readily modifiable for protocol updates.

Social media mining in drug development—Fundamentals and use cases

The incorporation of patients' perspectives into drug discovery and development has become critically important from the viewpoint of accounting for modern-day business dynamics. There is a trend among patients to narrate their disease experiences on social media. The insights gained by analyzing the data pertaining to such social-media posts could be leveraged to support patient-centered drug development. Manual analysis of these data is nearly impossible, but artificial intelligence enables automated and cost-effective processing, also referred as social media mining (SMM). This paper discusses the fundamental SMM methods along with several relevant drug-development use cases.     

全科门诊接诊家庭暴力受害者的技巧分析

家庭暴力受害者可同时遭受身体安全威胁和心理创伤折磨,导致受害者会因多种多样的生理和/或心理问题咨询全科医生。全科医生在面对家庭暴力受害者时,需要及时识别患者,充分评估和正确处理。但在临床实践中,全科医生遇到此类患者存在着手困难、缺乏问诊技巧、无恰当处理方式等诸多问题,因而多选择无视或简单转诊。本文通过对家庭暴力案例的接诊分析,讨论应用“以患者为中心”的方法和“生物-社会-心理医学模式”进行诊疗活动的技巧,充分体现全科医生价值所在,延伸以家庭为单位的治疗理念。     

Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic chronic lung disease affecting predominantly older adults, with a history of smoking. The current model of disease natural course is that recurrent injury of the alveolar epithelium in the context of advanced aging/cellular senescence is followed by defective re-epithelialization and scar tissue formation. Currently, two drugs, nintedanib and pirfenidone, that modify disease progression have been approved worldwide for the treatment of IPF. However, despite treatment, patients with IPF are not cured, and eventually, disease advances in most treated patients. Enhancing biogenomic and metabolic research output, its translation into clinical precision and optimal service delivery through patient-centeredness are key elements to support effective IPF care. In this review, we summarize therapeutic options currently investigated for IPF based on the major pathogenetic pathways and molecular targets that drive pulmonary fibrosis.